Related references
Note: Only part of the references are listed.Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis
Konstantinos P. Economopoulos et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
MDM2 SNP309 Associates With Accelerated Pancreatic Adenocarcinoma Formation
Lukasz F. Grochola et al.
PANCREAS (2010)
Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer
Ying-Fang Sun et al.
BMC CANCER (2009)
A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer
Hongmei Nan et al.
CANCER CAUSES & CONTROL (2009)
TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility
Thuy N. Do et al.
CANCER GENETICS AND CYTOGENETICS (2009)
MDM2 309 T/G polymorphism is associated with lung cancer risk among Asians
Xian-Hua Gui et al.
EUROPEAN JOURNAL OF CANCER (2009)
Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer
Katie A. Ashton et al.
GYNECOLOGIC ONCOLOGY (2009)
Interaction of Helicobacter pylori with Genetic Variants in the MDM2 Promoter, is Associated with Gastric Cancer Susceptibility in Chinese Patients
Xiaoyong Wang et al.
HELICOBACTER (2009)
Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer
Osamu NUNOBIKI et al.
Human Cell (2009)
Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer
Masatsugu Ueda et al.
HUMAN CELL (2009)
Association of p73 and MDM2 Polymorphisms With the Risk of Epithelial Ovarian Cancer in Chinese Women
Shan Kang et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis
V. Marcel et al.
JOURNAL OF MEDICAL GENETICS (2009)
Cigarette Smoking, MDM2 SNP309, Gene-Environment Interactions, and Lung Cancer Risk: A Meta-Analysis
Jianling Bai et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES (2009)
Polymorphisms at p53, p73, and MDM2 Loci Modulate the Risk of Tobacco Associated Leukoplakia and Oral Cancer
Chaitali Misra et al.
MOLECULAR CARCINOGENESIS (2009)
Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia
Xiujuan Xiong et al.
LEUKEMIA RESEARCH (2009)
Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing
Shiang-Fu Huang et al.
ORAL ONCOLOGY (2009)
MDM2 SNP309 Genotype Influences Survival of Metastatic But Not of Localized Neuroblastoma
Chiara Perfumo et al.
PEDIATRIC BLOOD & CANCER (2009)
Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population
Jyh-Der Leu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
MDM2 SNP309T > G polymorphism and risk of hepatocellular carcinoma: A case-control analysis in a Moroccan population
Sayeh Ezzikouri et al.
CANCER DETECTION AND PREVENTION (2009)
Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women
Virendra Singh et al.
ANNALS OF EPIDEMIOLOGY (2008)
Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene
Kirstin Mittelstrass et al.
BMC CANCER (2008)
MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism
Fiona E. M. Paulin et al.
BMC CANCER (2008)
Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics
R. Stoehr et al.
BRITISH JOURNAL OF CANCER (2008)
MDM2 SNP309 is associated with endometrial cancer risk
Kathryn Terry et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection
Young Joon Yoon et al.
CARCINOGENESIS (2008)
MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population
San San Lum et al.
CARCINOGENESIS (2008)
Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness:: Results of a pilot study on 239 patients
Sara Cattelani et al.
CLINICAL CANCER RESEARCH (2008)
MDM2 promoter polymorphism and pancreatic cancer risk and prognosis
Kofi Asomaning et al.
CLINICAL CANCER RESEARCH (2008)
MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients
Beng Hooi Phang et al.
EUROPEAN JOURNAL OF CANCER (2008)
The MDM2-309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia
Thorsten Zenz et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk
Geoffrey Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme
Rina G. Khatri et al.
JOURNAL OF NEUROSURGERY (2008)
Mdm2 promotes genetic instability and transformation independent of p53
Alyssa Bouska et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
MDM2 SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk
Daniel Krekac et al.
ONCOLOGY (2008)
MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent
Ronit I. Yarden et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility:: Evidence from 21 case-control studies
Zhibin Hu et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
No association of MDM2 SNP309 with risk of glioblastoma and prognosis
Soufiane El Hallani et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
MDM2 SNP309 and cancer risk: a combined analysis
Stefan Wilkening et al.
CARCINOGENESIS (2007)
Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer
Ming Yang et al.
CARCINOGENESIS (2007)
No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin
S. Wilkening et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling
Marijke Wasielewski et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses' health studies
David G. Cox et al.
CANCER CAUSES & CONTROL (2007)
MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma
Hiroshi Hirata et al.
CLINICAL CANCER RESEARCH (2007)
MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population
Gangqiao Zhou et al.
CLINICAL CANCER RESEARCH (2007)
Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis
Hiromasa Tsuiki et al.
NEUROLOGIA MEDICO-CHIRURGICA (2007)
Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk
Christine S. Walsh et al.
GYNECOLOGIC ONCOLOGY (2007)
Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells
Hafid Alazzouzi et al.
JOURNAL OF MEDICAL GENETICS (2007)
No association between SNP309 promoter polymorphism in the MDM2 and cervical cancer in a study from northeastern Brazil
Rosely de Vasconcellos Meissner et al.
CANCER DETECTION AND PREVENTION (2007)
MDM2 309T>G polymorphism and risk of lung cancer in a Korean population
Sun Ha Park et al.
LUNG CANCER (2006)
MDM2 gene promoter polymorphisms and risk of lung cancer:: a case-control analysis
Guojun Li et al.
CARCINOGENESIS (2006)
MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis
Naoki Ohmiya et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer
Ian G. Campbell et al.
CANCER LETTERS (2006)
Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population
Hongxia Ma et al.
CANCER LETTERS (2006)
MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C
Narayan Dharel et al.
CLINICAL CANCER RESEARCH (2006)
Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer
Helge Lind et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Association of breast cancer outcome with status of p53 and MDM2 SNP309
Brenda J. Boersma et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population
ZB Hu et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status
C Menin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer.
S Wilkening et al.
CANCER RESEARCH (2006)
Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer
XM Zhang et al.
HUMAN MUTATION (2006)
The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma
Y Hong et al.
CANCER RESEARCH (2005)
p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome
K Sotamaa et al.
CLINICAL CANCER RESEARCH (2005)
MDM2 is a central node in the p53 pathway: 12 years and counting
GL Bond et al.
CURRENT CANCER DRUG TARGETS (2005)
The MDM2 promoter polymorphism SNP309T -> G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck
P Alhopuro et al.
JOURNAL OF MEDICAL GENETICS (2005)
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
GL Bond et al.
CELL (2004)
Mutational spectrum of p53 mutations in primary breast and ovarian tumors
A Feki et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2004)
Regulation of p53: intricate loops and delicate balances
M Oren et al.
BIOCHEMICAL PHARMACOLOGY (2002)
Share Paper
